Wednesday, July 8, 2026

biotech · TCR-T Cells · B-ALL · TCRX

TScan Therapeutics

TScan Therapeutics is a biotech organization headquartered in Waltham, USA. It trades on NYSE under ticker TCRX. Primary therapeutic focus areas include TCR-T Cells, B-ALL, Solid Tumor, Non-Hodgkin Lymphoma, Advanced Sol

Waltham, USA HQ
2018 Founded
152 Employees
Public company Type
TCRX · NYSE Ticker
Company details
Status
Public
HQ
Waltham, USA
Founded
2018
Employees
152
Programs
9
Drugs
5
Patents
0
Clinical program

KSH01 injection

Phase 1 · small molecule · Solid Tumor

KSH01 injection for Solid Tumor is a Phase 1 program (small_molecule) at TScan Therapeutics with 1 ClinicalTrials.gov record(s).

← All TScan Therapeutics projects Phase 1 small molecule active

Internal code KSH01-R02-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
TScan Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Solid Tumor
Status
active
Trials
1

Clinical trials